AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at approximately $8.7 billion, is a strategic move that enhances AbbVie’s neuroscience portfolio by adding a robust pipeline of multiple clinical-stage and preclinical candidates. These candidates hold potential across several diseases, […]
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), for $31.26 per share in cash, totaling an equity value of approximately $10.1 billion. ELAHERE: A Breakthrough in Cancer Treatment The acquisition is a […]
US biopharma company AbbVie has wrapped up its previously announced $63 billion acquisition of Irish drugmaker Allergan following receipt of all the required approvals from all government authorities and approval from the Irish High Court. AbbVie acquisition of Allergan, which was announced in June 2019, is said to expand and diversify significantly the former’s revenue […]
